Parkinson's Disease: key endpoint results by drug
The key endpoints of Parkinson's Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Parkinson's Disease page.
OFF time, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| foslevodopa/foscarbidopa | -2.8 | -1.0 (LD/CD) | — | wk 12 · n 47 | NCT04380142 Phase 3, secondary |
| istradefylline | 4 | 4.2 | −0.2 | 20 mg/Day · wk 12 · n 194 | NCT01968031 Phase 3, primary |
| Levodopa-carbidopa intestinal gel | -4.0 | -2.1 (Levodopa-Carbidopa Capsules) | — | wk 12 · n 35 | NCT00357994 Phase 3, primary |
| Levodopa/carbidopa (ND0612) | -2.1 | -1.4 | −0.7 | wk 2 · n 19 | NCT01883505 Phase 2, secondary |
| Perampanel | -2.1 | -1.3 | −0.8 | wk 10 · n 15 | NCT00165789 Phase 2, secondary |
| Rasagiline (Azilect) | -1.3 | -0.8 | −0.5 | wk 16 · n 158 | NCT01479530 Phase 3, primary |
| rotigotine | -2.1 | -0.7 | −1.4 | wk 12 · n 54 | NCT01628848 Phase 2, secondary |
| Safinamide | -1.9 | -0.9 | −1 | wk 16 · n 151 | NCT03881371 Phase 3, primary |
| Solengepras (CVN424) | -1.6 | -0.5 | −1.1 | 150 mg · wk 4 · n 44 | NCT04191577 Phase 2, secondary |
| Tavapadon | -1.6 | -0.9 | −0.8 | wk 11 · n 242 | NCT04542499 Phase 3, secondary |
Drugs checked with no result here: 7 trial running, 18 not reported, 7 not posted.
ON time without troublesome dyskinesia, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Amantadine ER (Gocovri/ADS-5102) | 3.6 | 0.9 | +2.7 | 420 mg · wk 8 · n 19 | NCT01397422 Phase 2/3, secondary |
| foslevodopa/foscarbidopa | 2.7 | 1.0 (LD/CD) | — | wk 12 · n 47 | NCT04380142 Phase 3, primary |
| istradefylline | 10.7 | 10.1 | +0.6 | 20 mg/Day · wk 12 · n 194 | NCT01968031 Phase 3, secondary |
| Levodopa-carbidopa intestinal gel | 4.1 | 2.2 (Levodopa-Carbidopa Capsules) | — | wk 12 · n 35 | NCT00357994 Phase 3, secondary |
| Tavapadon | 1.7 | 0.6 | +1.1 | wk 26 · n 153 | NCT04542499 Phase 3, primary |
Drugs checked with no result here: 9 trial running, 17 not reported, 11 not posted.
UPDRS Part III, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| istradefylline | 19.7 | 19.4 | +0.3 | 20 mg/Day · wk 12 · n 194 | NCT01968031 Phase 3, secondary |
| Levodopa (Inbrija) | -9.8 | -5.9 | −3.9 | wk 12 · n 114 | NCT02240030 Phase 3, primary |
| Levodopa-carbidopa intestinal gel | -1.5 | -2.9 (Levodopa-Carbidopa Capsules) | — | wk 12 · n 36 | NCT00357994 Phase 3, secondary |
| Pramipexole | -10.2 | -9.9 (Pramipexole IR) | — | wk 12 · n 56 | NCT00560508 Phase 2/3, secondary |
| Pramipexole ER (Mirapex ER) | -8.3 | -4.3 | −4 | wk 18 · n 161 | NCT00466167 Phase 3, secondary |
| rotigotine | -10.9 | -4.5 | −6.4 | wk 16 · n 164 | NCT01628926 Phase 3, primary |
| Rytary (IPX066) | 21.6 | 25.5 (IR CD-LD) | — | wk 0 · n 27 | NCT00869791 Phase 2, secondary |
Drugs checked with no result here: 9 trial running, 15 not reported, 11 not posted.
MDS-UPDRS Part II, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Buntanetap | -0.0 | -0.1 | +0.1 | 20 mg · n 152 | NCT05357989 Phase 3, primary |
| foslevodopa/foscarbidopa | -2.6 | -1.1 (LD/CD) | — | wk 12 · n 46 | NCT04380142 Phase 3, secondary |
| Rasagiline (Azilect) | 0.1 | 2.3 | −2.2 | 1 mg · wk 26 · n 116 | NCT02337725 Phase 3, secondary |
| Solengepras (CVN424) | -0.3 | 0 | −0.3 | 150 mg · wk 12 · n 32 | NCT06006247 Phase 2, secondary |
| Tavapadon | -1.7 | 0.9 | −2.6 | 15 mg · wk 26 · n 116 | NCT04201093 Phase 3, secondary |
Drugs checked with no result here: 18 not reported, 7 trial running, 12 not posted.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 42 approved or late-stage drugs with a featured trial in Parkinson's Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.